Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28423201 | 0.81 | PTGS2 (0.50) | PTGS2 | |
| SCHEMBL8552206 | 0.78 | PTGS1 (0.41) | PTGS2PTGS1ADORA3 | |
| SCHEMBL30527899 | 0.76 | ALDH1A1 (0.41) | ALDH1A1ADORA3 | |
| SCHEMBL979621 | 0.75 | CFTR (0.43) | PTGS1ALDH1A1 | |
| SCHEMBL6602632 | 0.74 | PTGS1 (0.43) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL30527907 | 0.74 | CYP1A2 (0.38) | ALDH1A1 | |
| SCHEMBL30527856 | 0.74 | KMT2A (0.31) | — | |
| SCHEMBL10174659 | 0.74 | EGFR (0.41) | ALDH1A1 | |
| SCHEMBL8708120 | 0.74 | PTGS2 (0.46) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL2167797 | 0.74 | BACE1 (0.52) | PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0970067-B1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES WITH OXYGEN LINK AS COX-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-07-02 | — | — | EP | claimed |
| CN-103889453-A | Tumor selective chemokine modulation | KALINSKI PAWEL | 2014-06-25 | — | — | CN | disclosed |
| EP-1898941-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1888050-A2 | CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888051-A2 | SULPHONAMIDO-SUBSTITUTED CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006123182-A2 | CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006123184-A2 | SULPHONAMIDO-SUBSTITUTED CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-20040235826-A1 | Tyrosine kinase ihnibitors | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| EP-0724566-A1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995011883-A1 | 1,2-DIARYLCYCLOPENTENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235826-A1 | Tyrosine kinase ihnibitors | KDR, FLT4, ERBB2 | PTGS2 1192/4885PTGS1 929/4885ABCB11 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.